# Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivikar Tab. 5/40 mg in Healthy Adult Male Subjects

> **NCT02955498** · PHASE1 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Healthy Male Subjects

## Interventions

- **DRUG:** Sevikar tab. 10/40mg
- **DRUG:** Lodivikar tab. 5/40mg

## Key facts

- **NCT ID:** NCT02955498
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02955498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02955498, "Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivikar Tab. 5/40 mg in Healthy Adult Male Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02955498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*